First-ever treatment in multiple sclerosis.

CONCLUSIONS: Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity. PMID: 32771209 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32771209?dopt=Abstract

Source: Revue Neurologique - August 13, 2020 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research